4487-05-2

Usage

Uses

Used in Pharmaceutical Research:
1-Benzyl-4-(4-aminobutyl)piperazine is used as a potential antipsychotic agent for its ability to modulate dopamine receptor activity, which may contribute to the treatment of various psychiatric disorders.
Used in Dopamine Receptor Agonist Studies:
1-Benzyl-4-(4-aminobutyl)piperazine is used as a dopamine receptor agonist in preclinical studies, where it has demonstrated promising results in modulating dopaminergic pathways, potentially leading to advancements in the treatment of neurological and neurodegenerative diseases.
Used in Medicinal Chemistry Applications:
1-Benzyl-4-(4-aminobutyl)piperazine is used as a versatile molecule in medicinal chemistry for its structural features, allowing for the development of novel compounds with potential therapeutic applications in various medical fields.

Upstream product

• 4487-04-1 2-(4-(4-benzylpiperazin-1-yl)butyl)isoindoline-1,3-dione 
• 2759-28-6 1-phenylmethylpiperazine 

Downstream Products

• 120301-41-9 (E)-N-[4-(4-Benzyl-piperazin-1-yl)-butyl]-3-phenyl-acrylamide 
• 1351411-85-2 N-(4-(4-benzylpiperazin-1-yl)butyl)adamantane-1-carboxamide 
• 1351411-82-9 N-(4-(4-benzylpiperazin-1-yl)butyl)cyclohexanecarboxamide 
• 1351411-84-1 N-(4-(4-(6-nitropyridin-2-yl)piperazin-1-yl)butyl)cyclohexanecarboxamide 
• 1351411-83-0 N-(4-(piperazin-1-yl)butyl)cyclohexanecarboxamide 

Relevant academic research and scientific papers

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.

RADIOLABELED COMPOUNDS AND METHODS THEREOF

The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.